CNP Variants for Osteoarthritis Cartilage Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoarthritis primarily focus on reducing inflammation, offering only temporary pain relief without addressing the underlying joint degeneration or altered joint architecture.
Innovation Solution
The use of CNP variants, such as Gly-CNP-37 and Pro-Gly-CNP-37, which have longer half-lives and can be administered to treat osteoarthritis, promoting cartilage growth, reducing joint degeneration, and improving joint mobility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-inflammatory treatments are used, then pain relief is provided, but the underlying joint degeneration is not addressed and effects are only temporary
Solution Approach 1:
The patent uses CNP variants as intermediary substances that mediate between the administered treatment and the target joint tissues. These variants specifically target cartilage and bone cells to promote regeneration while simultaneously reducing inflammation, thereby addressing both the temporary relief limitation and the underlying degeneration problem through a single mediating agent
Solution Approach 2:
The patent modifies the amino acid sequence parameters of native CNP to create variants with enhanced stability and extended half-life. By changing specific amino acid residues (e.g., substituting proline at position 18, modifying N-terminal residues), the therapeutic duration is extended from hours to days, transforming the temporary relief characteristic into sustained treatment effect
2Object-affected harmful factors
If CNP is administered to promote cartilage growth, then joint degeneration is reduced, but the short half-life limits therapeutic effectiveness
Solution Approach 1:
The patent systematically modifies amino acid parameters of CNP to enhance its metabolic stability. Specific substitutions include replacing residues susceptible to proteolytic cleavage, adding disulfide bridges through cysteine substitutions, and modifying N-terminal sequences to resist degradation. These parameter changes extend the half-life from minutes to hours or days, enabling sustained therapeutic action
Solution Approach 2:
The patent creates composite peptide structures by fusing CNP with stabilizing domains or conjugating to carrier molecules. These composite structures provide both the biological activity of CNP and the enhanced stability of the fused/conjugated elements, effectively extending half-life while maintaining cartilage-promoting functions
3Object-affected harmful factors
If anti-inflammatory treatments are used, then inflammation is reduced, but cartilage regeneration and joint structure restoration are not achieved
Solution Approach 1:
The patent designs CNP variants with multi-functional capabilities: they bind to NPR-B receptors to stimulate cartilage and bone formation, activate anti-inflammatory pathways to reduce synovial inflammation, and promote angiogenesis to improve joint tissue health. This single agent performs multiple therapeutic functions that were previously required separate treatments, achieving both inflammation reduction and structural restoration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Administration of CNP variants leads to improved range of motion in affected joints and slowed or decreased osteoarthritis-associated damage to cartilage, calcified cartilage, or subchondral bone, providing longer-lasting relief for OA patients.
Implementation Method 1
NPR-B is a member of the membrane bound guanylyl cyclase multi-gene family and produces the second messenger cyclic guanosine monophosphate (cGMP) when activated by CNP binding
Data Source
AI summary
The disclosure relates to the use of variants of C-type natriuretic peptide (CNP) to treat osteoarthritis, to ameliorate one or more symptoms of osteoarthritis, and to treat disorders having an osteoarthritis component.